The Effects of Fructose Intake on Serum Uric Acid Vary among Controlled Dietary Trials

D. David Wang, John L. Sievenpiper, Russell J. de Souza, Laura Chiavaroli, Vanessa Ha, Adrian I. Cozma, Arash Mirrahimi, Matthew E. Yu, Amanda J. Carleton, Marco Di Buono, Alexandra L. Jenkins, Lawrence A. Leiter, Thomas M. S. Wolfer, Joseph Beyene, Cyril W. C. Kendall, and David J. A. Jenkins

Abstract

Hyperuricemia is linked to gout and features of metabolic syndrome. There is concern that dietary fructose may increase uric acid concentrations. To assess the effects of fructose on serum uric acid concentrations in people with and without diabetes, we conducted a systematic review and meta-analysis of controlled feeding trials. We searched MEDLINE, EMBASE, and the Cochrane Library for relevant trials (through August 19, 2011). Analyses included all controlled feeding trials investigating the effect of fructose feeding on uric acid under isocaloric conditions, where fructose was isocalorically exchanged with other carbohydrate, or hypercaloric conditions, and where a control diet was supplemented with excess energy from fructose. Data were aggregated by the generic inverse variance method using random effects models and expressed as mean difference (MD) with 95% CI. Heterogeneity was assessed by the Q statistic and quantified by I². A total of 21 trials in 425 participants met the eligibility criteria. Isocaloric exchange of fructose for other carbohydrate did not affect serum uric acid in diabetic and nondiabetic participants (MD = 0.56 μmol/L (95% CI: –0.62, 7.74)), with no evidence of inter-study heterogeneity. Hypercaloric supplementation of control diets with fructose (+35% excess energy) at extreme doses (213–219 g/d) significantly increased serum uric acid compared with the control diets alone in nondiabetic participants (MD = 31.0 mmol/L (95% CI: 15.4, 46.5)) with no evidence of heterogeneity. Confounding from excess energy cannot be ruled out in the hypercaloric trials. These analyses do not support a uric acid-increasing effect of isocaloric fructose intake in nondiabetic and diabetic participants. Hypercaloric fructose intake may, however, increase uric acid concentrations. The effect of the interaction of energy and fructose remains unclear. Larger, well-designed trials of fructose feeding at “real world” doses are needed.

Introduction

Metabolic syndrome predisposes individuals to diabetes and cardiovascular disease and affects over one-quarter of Americans and Canadians, making it an important public health concern (1,2). Metabolic syndrome is now defined as the presence of any 3 of the following 5 risk factors: elevated waist circumference [central obesity], elevated blood pressure (130/85 mm Hg) or antihypertensive drug treatment, or elevated fasting glucose (≥1.3 mmol/L for women) or drug treatment for low HDL cholesterol (<1.0 mmol/L for men, <1.3 mmol/L for women) or drug treatment for low HDL cholesterol, low HDL cholesterol (<1.0 mmol/L for men, <1.3 mmol/L for women) or drug treatment for low HDL cholesterol, elevated blood pressure (≥130/85 mm Hg) or antihypertensive drug treatment, or elevated fasting glucose (≥5.6 mmol/L) or drug treatment for elevated blood glucose (3). Meanwhile, uric acid is commonly associated with gout, an inflammatory condition affecting 8.3 million Americans (4). Further, hyperuricemia has been shown to be associated with components of metabolic syndrome, including hypertension and diabetes (5–7). Hyperuricemia is associated with obesity, excessive alcohol intake, and...
kidney failure (5). Uric acid concentrations have increased recently and the prevalence of hyperuricemia in U.S. adults is estimated at 21.4% (4). Proposed mechanisms of uric acid–mediated metabolic syndrome include the inhibition of endothelial NO leading to hypertension; inflammation and oxidative stress in adipocytes leading to insulin resistance; and increased endothelial and smooth muscle oxidative stress (6,7).

Dietary factors are thought to be important modulators of serum uric acid. Worldwide fructose intake, particularly in the form of high fructose corn syrup, has paralleled the rise in metabolic syndrome and hyperuricemia (8). High fructose consumption is associated with features of metabolic syndrome through an effect on uric acid (9,10). Fructose metabolism can promote uric acid formation (7). Once absorbed into the cell, unregulated phosphorylation of fructose by fructokinase leads to local ATP depletion and increased AMP production, which in turn increases uric acid (7). Early acute human studies demonstrated elevated serum uric acid after fructose feeding (11). Evidence from longer term fructose feeding trials (12–27) and observational studies (10,28–32), however, have shown mixed results.

2 Author disclosures: J. L. S. has received consultant fees, travel funding, honoraria, or additional research support from the CIHR, Calorie Control Council, The Coca-Cola Company, Archer Daniels Midland, International Life Sciences Institute (ILSI) North America and Brazil, Abbott Laboratories, and Pulse Canada. R.J. D. S. and J. B. have received additional research support from the CIHR and The Coca-Cola Company. T. M. S. W. is a part owner and the President of Glycemic Index Laboratories, Toronto, Canada and has authored several popular diet books on the glycemic index for which he has received royalties from Phillipa Sandall Publishing Services and CAB1 Publishers. He has received consultant fees, honoraria, travel funding, or additional research support from or served on the Scientific Advisory Board for CIHR, Canadian Diabetes Association (CDA), Dairy Farmers of Canada, McCain Foods, Temasek Polytechnic, Northwestern University, Royal Society of London, Glycemic Index Symbol program, CreaNutrition AG, McMaster University, Canadian Society for Nutritional Sciences, National Sports and Conditioning Association, Faculty of Public Health and Nutrition–Autonomous University of Nuevo Leon, Diabetes and Nutrition Study Group of the European Association for the Study of Diabetes. C.W.C.K. has received consultant fees, honoraria, travel funding, or additional research support from or served on the Scientific Advisory Board for the CIHR, The Coca Cola Company, Abbott Laboratories, Advanced Food Materials Network, Almond Board of California, American Peanut Council, American Pistachio Growers, Barilla, California Strawberry Commission, Canola Council of Canada, Danone, General Mills, Hain Celestial, International Tree Nut Council, Kellogg, Loblaw’s Supermarkets Ltd, Orafti, Orfruits, Paramount Farms, Pulse Canada, Saskatchewan Pulse Growers, Solae and Unilever. D. J. A. J. has received consultant fees, honoraria, travel funding, or additional research support from or served on the Scientific Advisory Board for the Calorie Control Council, The Coca Cola Company, Barilla, Solae, Unilever, Hain Celestial, Loblaw’s Supermarkets Inc., Sanitarium Company, Herbalife International, Pacific Health Laboratories Inc., Metagenics/MetaProteomics, Bayer Consumer Care, Odlaweys Preservation Trust, The International Tree Nut Council Nutrition Research & Education, The Peanut Institute, Procter and Gamble Technical Centre Limited, Griffin Hospital for the development of the NuVal System, Soy Advisory Board of Dean Foods, Alpro Soy Foundation, Nutritional Fundamentals for Health, Pacific Health Laboratories, Kellogg’s, Quaker Oats, The Coca-Cola Sugar Advisory Board, Pepsi Company, Agrifoods and Agriculture Canada (AAFC), Canadian Agriculture Policy Institute (CAPI), The Almond Board of California, The California Strawberry Commission, Orfruits, the Canola and Flax Councils of Canada, Pulse Canada, the Saskatchewan Pulse Growers, and Abbott Laboratories. D. J. A. J. also holds additional grant support from the CIHR, Canadian Foundation for Innovation (CFI), Ontario Research Fund (ORF), and Advanced Foods and Material Network (AFMN/Net). A. L. J. is a part owner, Vice-President, and Director of Research of Glycemic Index Laboratories, Toronto, Ontario, Canada. She has received additional research support from the CDA. L. C. is a casual Clinical Research Coordinator at Glycemic Index Laboratories, Toronto, Canada, L. C. V. H., and A. J. C. have received additional research support from the CDR. D. D. W., A. I. C., M. E. Y., A. J. C., M. D., and L. A. L. have no declared conflicts of interest related to this paper.

3 This systematic review was registered at clinicaltrials.gov as NCT01363791.

4 Supplemental Table 1 and Supplemental Figure 1 are available from the “Online Supporting Material” link in the online posting of the article and from the same link in the online table of contents at jn.nutrition.org.

There are currently no recommendations addressing the effect of dietary fructose intake on uric acid and the risk of gout or metabolic syndrome. Various health agencies, including the American Diabetes Association, the European Association for the Study of Diabetes, and the AHA, have discouraged high intakes of fructose based on adverse affects on serum lipids (33–35). To evaluate the need for additional clinical evidence regarding the effects of fructose consumption on uric acid in humans, we conducted a systematic review and meta-analysis of controlled feeding trials to assess the effect of fructose on uric acid.

Methods

This systematic review and meta-analysis followed a similar methodological approach as Sievenpiper et al. (36). We followed the Cochrane Handbook for Systematic Reviews of Interventions for the planning and conduct of this meta-analysis (37). The reporting followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines (38,39).

Study selection. We conducted a search of MEDLINE (1948 through August 19, 2011), EMBASE (1974 through August 19, 2011), and the Cochrane Central Register of Controlled Trials database (1950 through August 19, 2011) using the search terms: fructose AND (uric acid OR urate). Inclusion criteria is listed in Supplemental Table 1.

Data extraction. Three reviewers (D.W., V.H., L.C.) independently extracted the following study characteristics: design (parallel or crossover), randomization, blinding, sample size, participant characteristics (age, sex, BMI, and diabetes status), fructose form (solid, liquid, or mixed), dose, control reference carbohydrates (sucrose, starch, glucose), follow-up, and the macronutrient profile of the background diet. The quality of each study was assessed by each reviewer using the Heyland methodological quality score (MQS)13 (40), which assigns a score from 0 to 1 or 0 to 2 in 9 categories of quality related to study design, sampling procedures, and interventions for a total of 13 points. Disagreements were reconciled by consensus through discussion with another investigator (J.L.S.). The fasting serum uric acid concentration (mean ± SD) was extracted as the main endpoint. All trials reported end differences. We calculated missing SD values from available statistics using standard formula (37). Where these data were not reported preventing calculation, we imputed SD values using a pooled correlation coefficient derived from a meta-analysis of correlation coefficients from those trials reporting sufficient data. We derived correlation coefficients for individual trials according to a standard formula (37,41). We then input these values into the meta-analysis as transformed Z-scores ≥ 5E, from which we derived the pooled correlation coefficient. If SD coefficients still could not be imputed, then we derived the missing SD from the pooled SD imputed for the other trials (42).

Statistical analyses. Data were analyzed using Review Manager (RevMan) version 5.0.25 (The Nordic Cochrane Centre, The Cochrane Collaboration). Separate pooled analyses for isocaloric and hypercaloric fructose feeding trials were conducted using the Generic Inverse Variance method using random effects models. Analyses were stratified by diabetes and nondiabetes. The outcome studied was end differences in serum uric acid. Potential sources of methodological heterogeneity were investigated by sensitivity analyses and a priori subgroup analyses, investigating the effect of comparator (starch, sucrose, glucose)1/ fructose format (fluid, mixed, solid), dose [Canadian Diabetes Association thresholds: <60 or ≥60 g/d (43)], follow-up (<4 wk, >4 wk), study quality [Heyland MQS <8, ≥8 (40)], randomization, and study design (parallel or crossover). Meta-regressions were performed to assess the significance of subgroup effects (STATA 11.2). Publication bias was investigated by visual inspection of funnel plots and formally tested using Begg (44) and Egger (45) tests.
Isocaloric trials

No diabetes

Crapo (15) 11 N; 4 M, 7 F 39.5 ± 11.4 330 ± 98.6 C IP, USA Supp No −81 (13.2) MX Suxrose 55:30:15 2 7
Forster (17) 6 N; 2 M, 4 F 23 (20–26) 309 ± 77 C IP, GER Met No 162 (33) MX Glucose 92:00:08 2 7
Hallfrisch (19) 12 N; 12 M, 0 F 39.8 ± 8.3 324 ± 82.3 P IP/OP, USA Met No −101 (15) SD Starch 43:42:15 5 7
Hallfrisch (19) 12 N; 12 M, 0 F 39.5 ± 7.3 371 ± 82 P IP/OP, USA Met No −101 (15) SD Starch 43:42:15 5 7
Huttunen (20) 68 N; 35 fructose, 33 sucrose 27.5 ± 7.0 320 ± 57.4 P OP, FIN Supp No 69.1 MX Suxrose — 95 5
Koh (21) 9 N; 3 M, 6 F 50 ± 15 333 ± 53.5 C IP/OP, USA PM No −78.5 (15) MX Glucose 52:32:16 4 8
Mademo (27) 10 N; 7 M, 10 2F 38.8 ± 8.8 329 ± 8.3 P OP, MEX Supp Yes −60 (13) MX Starch 55:30:15 6 6
Ngo Sock (23) 11 N; 11 M, 0 F 24 ± 2.0 330 ± 29.8 C OP, SUI Met Yes −213 (28) LG Glucose 55:30:15 1 8
Reiser (26) 11 N; 11 M, 0 F; 10 H; 10 M, 0 F 43.5 (23–64) 312 ± 82.3 C OP, USA Met No 167 (20) MX Starch 51:36:13 5 4

Hypercaloric trials

No diabetes

Anderson (12) 14 DM2; 14 M, 0 F 60 ± 4 360 ± 82.3 C OP, USA PM No −55 (12) MX Starch 55:25:20 23 8
Bantle (13) 12 DM2; 6 M, 6 F; 12 DM2; 5 M, 7 F 62 (36–60) 244 ± 82.3 C IP/OP, USA Met Yes −138.5 (21) MX Starch 55:30:15 1 1 8
Blayo (14) 11 DM2; 3 DM2 46.9 ± 13.1 232 ± 82.3 P OP, FRA Supp Yes −25 (5) MX Starch 55:30:15 52 7
Crapo (16) 7 DM2; 3 M, 4 F 50.9 ± 8.4 357 ± 158 C IP, USA Met No −97.5 (13.2) MX Suxrose 55:30:15 2 7
Griz rosco (18) 8 DM2; 5 M, 3 F 40.6 ± 9.3 354 ± 102 C OP, FRA Supp Yes 30 (8) LG Starch 50:20:80 2 8
Koh (21) 9 prediabetes; 3 M, 6 F 50 ± 15 396 ± 35.7 C IP, FRA PM No −78.5 (15) MX Suxrose 52:32:16 4 8
Osei (24) 13 DM2; 5 M, 8 F 54 ± 10.8 274 ± 111 C OP, USA Met Yes 60 (7.5) MX Suxrose 55:35:15 26 8
Osei (25) 18 DM2; 3 M, 15 F 57 ± 3.0 348 ± 144 P OP, USA Met Yes 60 (10) MX Starch 55:35:15 12 8

Diabetes/prediabetes

Anderson (12) 14 DM2; 14 M, 0 F 60 ± 4 360 ± 82.3 C OP, USA PM No −55 (12) MX Starch 55:25:20 23 8
Bantle (13) 12 DM2; 6 M, 6 F; 12 DM2; 5 M, 7 F 62 (36–60) 244 ± 82.3 C IP/OP, USA Met Yes −138.5 (21) MX Starch 55:30:15 1 1 8
Blayo (14) 11 DM2; 3 DM2 46.9 ± 13.1 232 ± 82.3 P OP, FRA Supp Yes −25 (5) MX Starch 55:30:15 52 7
Crapo (16) 7 DM2; 3 M, 4 F 50.9 ± 8.4 357 ± 158 C IP, USA Met No −97.5 (13.2) MX Suxrose 55:30:15 2 7
Griz rosco (18) 8 DM2; 5 M, 3 F 40.6 ± 9.3 354 ± 102 C OP, FRA Supp Yes 30 (8) LG Starch 50:20:80 2 8
Koh (21) 9 prediabetes; 3 M, 6 F 50 ± 15 396 ± 35.7 C IP, FRA PM No −78.5 (15) MX Suxrose 52:32:16 4 8
Osei (24) 13 DM2; 5 M, 8 F 54 ± 10.8 274 ± 111 C OP, USA Met Yes 60 (7.5) MX Suxrose 55:35:15 26 8
Osei (25) 18 DM2; 3 M, 15 F 57 ± 3.0 348 ± 144 P OP, USA Met Yes 60 (10) MX Starch 55:35:15 12 8

Results

Search results. The systematic search and selection of the literature is outlined (Supplemental Fig. 1). A total of 375 reports were identified as eligible from the initial search, of which 340 reports were excluded based on the title or abstract. The remaining 35 reports were retrieved and reviewed, whereas a further 19 were excluded. A total of 16 met the eligibility criteria and were included in this meta-analysis. These 16 reports contained 18 isocaloric trials (12–21,23–27) and 3 hypercaloric trials (22,23) and one of the reports contained both an isocaloric and hypercaloric trial (23).

Trial characteristics. Trial characteristics are shown in Table 1. Nine of the isocaloric trials were in 119 prediabetic and diabetic participants with 12 comparison arms and 9 of the isocaloric trials were in 271 nondiabetic participants with 8 comparison arms. The 3 hypercaloric trials were in 35 nondiabetic participants with 3 comparison arms. The mean age of participants was 42.6 y old (23–62 y old) in the isocaloric trials and 24.4 y old (24–24.6 y old) in the hypercaloric trials. Mean baseline uric acid was 317 μmol/L (232–398 μmol/L) in isocaloric trials and 312 μmol/L (300–322 μmol/L) in hypercaloric trials. Eight (44%) isocaloric trials and all 3 hypercaloric trials were randomized. Twelve (67%) isocaloric and all 3 hypercaloric trials used crossover designs. Starch (11 trial arms), sucrose (6 trial arms), or glucose (4 trial arms) were used as the comparator-carbohydrate in the isocaloric trials, whereas weight-maintaining control diets were used as the comparator in the hypercaloric trials. Fructose was administered in liquid, solid, or...
mixed formats at a mean dose of 94 g/d [25–213 g/d or 5–33% energy (E)] in the isocaloric trials and 215 g/d [213–219 g/d or +35% excess E] in the hypercaloric trials. Thirteen (72%) of the isocaloric trials and all 3 of the hypercaloric trials exceeded the dose threshold of 60 g/d proposed by the Canadian Diabetes Association (13,15–17,19,20,22,23,26). Nine (50%) isocaloric and all 3 hypercaloric trials used metabolically controlled designs. Background diets in the isocaloric and hypercaloric trials provided a wide range of macronutrient profiles. Isocaloric trial diets consisted of 43–92% E carbohydrate, 0–42% E fat, and 8–20% E protein. All hypercaloric trial diets consisted of 55% E carbohydrate, 30% E fat, and 15% E protein. The mean follow-up was 14.4 wk (1–95 wk) in the isocaloric trials, whereas all 3 hypercaloric trials lasted 1 wk. The Heyland MQS in the isocaloric trials ranged from 4 to 8 with 9 trials (50%) considered to be of higher quality (MQS ≥8). All hypercaloric trials were of higher quality with an MQS score of 8.

Isocaloric feeding trials. The effect of fructose in isocaloric exchange for other carbohydrate on uric acid was not significant in prediabetic/diabetic participants mean difference (MD) = −4.09 (95% CI: −23.7, 15.6) and nondiabetic participants [MD = 1.28 (95% CI: −6.65, 9.22)] (Fig. 1). The lack of effect was found consistently across trials without any evidence of inter-study heterogeneity ($I^2 = 0\%$ in both groups). Systematic removal of trials during sensitivity analyses did not alter the conclusions. There was no significant effect in any of the a priori subgroups and no significant evidence of heterogeneity (Fig. 2).

Hypercaloric feeding trials. There was a significant effect of hypercaloric (+35% E) fructose on serum uric acid in participants without diabetes (Fig. 3). A large uric acid-raising effect [MD = 31.0 (95% CI: 15.4, 46.5); $P < 0.05$] of hypercaloric (+35% E) fructose was seen without any evidence of inter-study heterogeneity ($I^2 = 0\%$; $P = 0.97$). A priori subgroup analyses were not conducted owing to an insufficient number of trials.

Publication bias. Funnel plots were inspected for the presence of publication bias (Fig. 4). There was a suggestion of funnel plot asymmetry with a lack of small trials favoring a uric-acid raising effect of fructose; however, neither Egger nor Begg tests provided sufficient evidence of publication bias for uric acid (Egger test, $P = 0.95$; Begg test, $P = 0.14$).

Discussion

The present pooled analyses of 21 controlled feeding trials in 425 prediabetic/diabetic and nondiabetic participants demonstrate that the uric acid response to fructose feeding differs

### TABLE 1

| Study or Subgroup | Year | N (any CHO) | N (fructose) | Mean difference in uric acid (μmol/L) |
|------------------|------|-------------|--------------|--------------------------------------|
| Diabetes and HI | 1988 | 14          | 14           |                                      |
| Anderson (12)    |      |             |              |                                      |
| Bantle (13) [DM1]| 1998 | 12          | 12           |                                      |
| Bantle (13) [DM2]| 1998 | 12          | 12           |                                      |
| Bleyo (14)       | 1990 | 14          | 6            |                                      |
| Crapo (16)       | 1986 | 11          | 11           |                                      |
| Grigorecu (18)   | 1988 | 8           | 8            |                                      |
| Koh (21) [IGT]   | 1988 | 9           | 9            |                                      |
| Osei (24)        | 1989 | 9           | 9            |                                      |
| Osei (25)        | 1987 | 13          | 13           |                                      |
| **Subtotal**     |      |             |              |                                      |
| **Heterogeneity:** Tau² = 0.00; Chi² = 3.06 df = 8 (P = 0.93); $I^2 = 0\%$  
**Test for overall effect:** Z = 0.41 (P = 0.68) |

| Not Diabetes | 1984 | 11          | 11           |                                      |
| Crapo (15)    | 1973 | 6           | 6            |                                      |
| Forster (17)  | 1986 | 12          | 12           |                                      |
| Hallfrisch (19) [HI] | 1986 | 12          | 12           |                                      |
| Hallfrisch (19) [N] | 1986 | 12          | 12           |                                      |
| Huttinen (20) | 1976 | 33          | 35           |                                      |
| Koh (21) [N]  | 1988 | 9           | 9            |                                      |
| Madero (27)   | 2011 | 57          | 52           |                                      |
| Ngo Sock (23) | 2009 | 11          | 11           |                                      |
| Reiser (26)   | 1989 | 21          | 21           |                                      |
| **Subtotal**  |      |             |              |                                      |
| **Heterogeneity:** Tau² = 1.75; Chi² = 8.05 df = 8 (P = 0.43); $I^2 = 1\%$  
**Test for overall effect:** Z = 0.32 (P = 0.75) |
| **Total**     |      |             |              |                                      |
| **Heterogeneity:** Tau² = 0.00; Chi² = 11.36 df = 17 (P = 0.84); $I^2 = 0\%$  
**Test for overall effect:** Z = 0.15 (P = 0.88) |

**FIGURE 1** Forest plots of feeding trials investigating the effect of isocaloric exchange of fructose for carbohydrate on uric acid in people with and without diabetes. Three pooled effect estimates (diamonds) are shown: one each for trials in individuals with diabetes, no diabetes, and their combination. Paired analyses were applied to all crossover trials. Data are for weighted MD with 95% CI in uric acid (μmol/L). Data are expressed as weighted MD with 95% CI using generic inverse variance random effects models. Inter-study heterogeneity was tested by Cochrane’s Q statistic (chi-square) at a significance level of $P < 0.10$ and quantified by $I^2$, where $I^2 \leq 50\%$ is considered to be evidence of substantial heterogeneity and $\geq 75\%$, considerable heterogeneity. CHO, any carbohydrate comparator; DM1, type 1 diabetes mellitus; DM2, type 2 diabetes mellitus; IGT, impaired glucose tolerance; HI, hyperinsulemia; MD, mean difference; N, normal.
between isocaloric and hypercaloric feeding conditions. Isocaloric fructose intake did not raise uric acid, whereas hypercaloric fructose intake did. The mean increase in the hypercaloric trials was 31.0\(\text{mmol/L}\).

The clinical and practical importance of the increase in uric acid in the hypercaloric trials is unclear. The 3 hypercaloric trials in this meta-analysis fed fructose at 35% excess E (852–876 kcal/d or 213–219 g/d) in fluid form in nondiabetic males for 1 wk, a level of exposure that is more than double the 95th percentile (87 g/d) of fructose intake in the US (46). At these tremendous doses, the resulting 31.0-\(\text{mmol/L}\) increase in uric acid has the potential to place many individuals at risk of hyperuricemia (>416 \(\text{mmol/L}\) in men or >339 \(\text{mmol/L}\) in women), where the mean serum urate concentrations in U.S. adults are 365 \(\text{mmol/L}\) in men and 290 \(\text{mmol/L}\) in women (4). Extreme fructose doses inducing hyperuricemia have also been studied in the past. Perez-Pozo et al. (10) conducted a randomized, 2-wk crossover trial in which participants were randomized to either allopurinol, a xanthine oxidase inhibitor which inhibits the production of uric acid, or placebo while consuming 200 g/d of fructose for 2 wk. Allopurinol was shown to decrease the fructose-induced rise in uric acid by 65 \(\text{mmol/L}\). Although this increase was reported under weight-maintaining conditions, the evidence from observational studies suggests that an excess of energy may be a prerequisite for a sustainable uric acid-increasing effect of fructose. In models not adjusted for total energy or carbohydrate intake, high fructose intake increased uric acid in the NHANES III (32); however, in energy- and nonfructose carbohydrate-adjusted models, no effect of total fructose was found on either uric acid concentrations or risk of gout in NHANES 1999–2004 (32). Although these data taken together with our findings highlight possible confounding from excess energy at high doses, the small number of trials in our hypercaloric analysis limits the confidence in our estimates.

In the isocaloric setting, there was no effect of fructose substitution for other carbohydrate on uric acid concentrations. This lack of effect contradicts data from the Health Professionals Follow-up study that found that sweetened soft drink intake (equivalent to \(\sim 100 \text{g/d}\) of fructose as high fructose corn syrup) was associated with a 29.1-\(\text{mmol/L}\) increase in uric acid.

### FIGURE 2
Subgroup analyses in the isocaloric feeding trials investigating the effect of isocaloric exchange of fructose for carbohydrate on uric acid in people with and without diabetes. Points for each subgroup level are the pooled effect estimates expressed as weighted MD with 95% CI using generic inverse variance random effect models. The dashed line represents the pooled effect estimate for the total analysis. CHO, any carbohydrate comparator; MD, mean difference.

### FIGURE 3
Forest plots of feeding trials investigating the effect of hypercaloric fructose feeding on serum uric acid under hypercaloric conditions, where a control diet was supplemented with excess energy from fructose, in people without diabetes. Data are for weighted MD with 95% CI in uric acid (\(\text{mmol/L}\)). Data are expressed as weighted MD with 95% CI using generic inverse variance random effects models. Inter-study heterogeneity was tested by Cochrane’s Q statistic (chi-square) at a significance level of \(P < 0.10\) and quantified by \(I^2\), where \(I^2 \geq 50\%\) is considered to be evidence of substantial heterogeneity and \(75\%\), considerable heterogeneity. CHO, any carbohydrate comparator; MD, mean difference; N, normal healthy participants; ODM2, offspring of type 2 diabetes mellitus.
concentrations (29). Similarly, an analysis of NHANES III found that isocaloric substitution of sugar-sweetened beverages (equivalent to $\sim16\%$ E as fructose) for other energy was associated with a 25.0-μmol/L increase in uric acid and a multivariate OR of 1.82 for hyperuricemia (29). The reason for the discordance between these observational data and our meta-analysis of controlled feeding trials is unclear. It is possible that there may be a threshold for fructose-mediated ATP depletion/AMP production, which is thought to lead to increased uric acid concentrations. The mean fructose dose in the isocaloric trials (9.4 g/d) was below the level of exposure associated with higher uric acid concentrations in the observational studies, which may also have incompletely adjusted for energy compensation. It was also well below the mean dose used in our included hypercaloric trials (215 g/d) used to induce higher uric acid concentrations and the animal models (60% E as fructose, which is equivalent to 300 g/d on a 2000-kcal diet) used to elucidate the mechanism of fructose-induced uric acid production (9). A fructose dose threshold has been observed in clinical trials, below which the effects on other metabolic biomarkers are lost, e.g., ≤60 g/d in type 2 diabetes (36) and <100 g/d across all subject types (47) for TG. Additionally, there is evidence of fructose intolerance and incomplete absorption at higher doses and concentrations, further confounding results from trials at high doses (48). Population-level intakes of fructose, where the 50th percentile of fructose intake in the US is 49 g/d (46), may be unlikely to elicit this mechanism in a clinically significant way. Both dose alone and dose in relation to excess energy, therefore, are important considerations in assessing adverse effects of fructose on uric acid.

The strength of the present analyses is the lack of both statistical heterogeneity and clinical heterogeneity. Neither stratification of the data nor a priori subgroup analyses altered the significance of the effect estimates or heterogeneity. The lack of an effect of fructose in isocaloric exchange for other carbohydrates on uric acid was robust to stratification by diabetes status. It was also not modified by dose at a lower threshold (≤ or >60 g/d), comparator (starch, sucrose, and glucose), follow-up (< or ≥4 wk), design (crossover, parallel), study quality (MQS ≥ or <8), randomization (yes, no), or fructose form (solid, liquid, mixed). Although not tested formally in subgroup analyses, composition of the background diet in the trials also did not appear to have an effect. One of the included isocaloric trials, Forster et al. (17), had a background diet devoid of fat. This study was included, because it met all eligibility criteria. Removal of this trial during sensitivity analyses did not alter the conclusions, although this trial should be interpreted cautiously. The consistency across these different trial conditions helps to strengthen the generalizability of our conclusions.

Our analyses, nevertheless, have several limitations. First, our literature search would not have identified trials that measured uric acid and displayed uric acid data but was only discussed within a table or figure. Second, the hypercaloric studies recruited only men; previous studies have shown both sex and hormone effects on uric acid concentrations. Men generally have higher concentrations of uric acid than women and hormones play a role. Estrogen can reduce uric acid concentrations, mitigating many of the metabolic effects of uric acid (49), whereas testosterone has been associated with increased uric acid (50). Although the data support increased uric acid concentrations in men, we could not determine from the existing data the effects of hypercaloric fructose on women. Third, only 5 of the included isocaloric trials and none of the hypercaloric trials were longer than 12 wk. Although we found no evidence of effect according to follow-up, it is unclear whether the lack of effect of isocaloric fructose exchange for another carbohydrates on uric acid would be sustainable over the long term. It is also unclear whether isocaloric exchange conditions can be maintained over the long term. Longer-term trials would be helpful in separating out the short-term from the longer-term effects of fructose. Fourth, study quality was poor (MQS <8) in 50% of the included trials. Complicating this issue was the incomplete reporting in many publications requiring a fair degree of imputations (718 trials required imputations). There was, however, no effect ($P = 0.97$) of MQS (<8 vs. ≥8) in subgroup analyses. Although the use of a quality scoring method, such as the MQS, may have been inadequate (51), the consistent lack of effect of all a priori subgroups (Fig. 2) supports the lack of a uric acid-raising effect ($P > 0.2$ for all comparisons) of isocaloric fructose exchange for other carbohydrates. Fifth, only two-thirds of the isocaloric trials used crossover designs. However, Lathyrus et al. (52) performed a systematic review of Cochrane Reviews and found generally good agreement between parallel and crossover trials. Finally, publication bias was a possibility in both the isocaloric and hypercaloric trials. Visual inspection of funnel plots for both sets of trials along with Egger or Begg tests found limited evidence of funnel plot asymmetry and publication bias.

In conclusion, our work suggests that contrary to concerns, isocaloric fructose exchange for other sources of carbohydrate does not raise uric acid concentrations and this lack of effect holds across different experimental conditions. These conclusions, however, are limited by the short follow-up of the majority of trials and poor quality of one-half of the trials included in the meta-analysis. On the other hand, high fructose intake (213–219 g/d) under hypercaloric feeding conditions (+35% E) does raise serum uric acid concentrations, although confounding from excess energy cannot be ruled out in these trials. These data highlight the need for larger and longer fructose feeding trials conducted under free-living conditions to assess whether fructose consumption leads to excess energy intake and whether in turn the effects on uric acid are dependent on excess energy.

Acknowledgments

D.D.W., J.L.S., R.J.d.S., A.M., A.J.C., M.D., A.J.I., L.A.L., T.M.S.W., J.B., C.W.C.K., and D.J.A.J. designed the research; D.D.W., J.L.S., R.J.d.S., L.C., V.H., A.I.C., and A.M. conducted the research; D.D.W., J.L.S., L.C., V.H., A.I.C., and R.J.d.S. performed the statistical analysis; D.D.W. and J.L.S. wrote the paper; and D.J.A.J. had primary responsibility for final content. All authors read and approved the final manuscript.
22. LeKA, Ith M, Kreis R, Faeh D, Bortolotti M, Tran C, Boesch C, Tappy L. Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes. Am J Clin Nutr. 2009;89:1760–5.

23. Ngo Sock ET, Le KA, Ith M, Kreis R, Boesch C, Tappy L. Effects of a short-term overfeeding with fructose or glucose in healthy young males. Br J Nutr. 2010;103:939–43.

24. Osei K, Bossetti B. Dietary fructose as a natural sweetener in poorly controlled type 2 diabetes: a 12-month crossover study of effects on glucose, lipoprotein and apolipoprotein metabolism. Diabet Med. 1989;6:506–11.

25. Osei K, Falko J, Bossetti BM, Holland GC. Metabolic effects of fructose as a natural sweetener in the physiologic meals of ambulatory obese patients with type II diabetes. Am J Med. 1987;83:249–55.

26. Reiser S, Powell AS, Scholfield DJ, Panda P, Ellwood KC, Canary JJ. Blood lipids, lipoproteins, apoproteins, and uric acid in men fed diets containing fructose or high-amylose cornstarch. Am J Clin Nutr. 1989;49:832–9.

27. Madero M, Arriaga JC, Jalal D, Rivard C, McFann K, Pérez-Méndez O, Vázquez A, Ruiz A, Lanasa MA, Jiménez CR, et al. The effect of two energy-restricted diets, a low-fructose diet versus a moderate natural fructose diet, on weight loss and metabolic syndrome parameters: a randomized controlled trial. Metabolism. 2011;60:1551–9.

28. Bomback AS, Derebail VK, Shoham DA, Anderson CA, Steffen LM, Rosamond WD, Khushsagar AV. Sugar-sweetened soda consumption, hyperuricemia, and kidney disease. Kidney Int. 2010;77:609–16.

29. Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ. 2008;336:309–12.

30. Choi JWJ, Ford ES, Gao X, Choi HK. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: The third National Health and Nutrition Examination Survey. Arthritis Rheum. 2008;59:109–16.

31. Gao X, Qi L, Qiao N, Choi HK, Curhan G, Tucker KL, Ascherio A. Intake of added sugar and sugar-sweetened drink and serum uric acid concentration in US men and women. Hypertension. 2007;50:306–12.

32. Sun SZ, Flickinger B, Williamson-Hughes P, Empie M. Lack of association between dietary fructose and hyperuricemia risk in adults. Nutr Metab (Lond). 2010;7:16.

33. American Diabetes Association, Bantle JP, Wylie-Roset J, Alburght AL, Apovian CM, Clark NG, Franz MJ, Hoogwerf BJ, Lichtenstein AH, Mayer-Davis E, et al. Nutrition recommendations and interventions for diabetes. Diabetes Care. 2008;2008:561–78.

34. Mann JJ, De Leeuw I, Hermansen K, Karamanos B, Karlström B, Katsilambros N, Riccardi G, Rivellese AA, Rizkalla S, Slama G, et al. Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus. Nutr Metab Cardiovasc Dis. 2004;14:373–94.

35. Müller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292–333.

36. Sievenpiper JL, Carleton AJ, Chatha S, Jiang HY, de Souza RJ, Beyene J, Kendall CW, Jenkins DJ. Heterogeneous effects of fructose on blood lipids in individuals with type 2 diabetes: systematic review and meta-analysis of experimental trials in humans. Diabetes Care. 2009;32:1930–7.

37. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011 2008 [cited January 30, 2012]. Available from: www.cochrane-handbook.org.

38. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet. 1999;354:896–900.

39. Moher D, Liberati A, Tetzlaff J, Altman DG, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.

40. Heyland DK, Novak F, Drover JW, Jain M, Su X, Suchner U. Should immunonutrition become routine in critically ill patients? A systematic review of the evidence. JAMA. 2001;286:944–53.

41. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol. 2002;31:140–9.

42. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol. 2006;59:7–10.
43. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diab. 2008;S1–201.
44. Begg CB. A measure to aid in the interpretation of published clinical trials. Stat Med. 1985;4:1–9.
45. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.
46. Marriott BP, Cole N, Lee E. National estimates of dietary fructose intake increased from 1977 to 2004 in the United States. J Nutr. 2009;139:S1228–35.
47. Livesey G. Fructose ingestion: dose-dependent responses in health research. J Nutr. 2009;139:S1246–52.
48. Kneempens CM, Vonk RJ, Fernandes J. Incomplete intestinal absorption of fructose. Arch Dis Child. 1984;59:735–8.
49. Sumino H, Ichikawa S, Kanda T, Nakamura T, Sakamaki T. Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricaemia. Lancet. 1999;354:650.
50. Denzer C, Muche R, Mayer H, Henze E, Debatin K-M, Wahitsch M. Serum uric acid levels in obese children and adolescents: linkage to testosterone levels and pre-metabolic syndrome. J Pediatr Endocrinol Metab. 2003;16:1225–32.
51. Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA. 1999;382:1074–60.
52. Lathyris DN, Trikalinos TA, Ioannidis JP. Evidence from crossover trials: empirical evaluation and comparison against parallel arm trials. Int J Epidemiol. 2007;36:422–30.